Q-omics provides the consensus-scored ANO8 profile across patient tissues and cancer cell-line models. ANO8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ANO8 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ANO8 RNA expression shows 19,626 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, COAD, and DLBC as cancer lineages where ANO8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANO8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANO8 survival associations across molecular data types. ANO8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANO8 RNA expression–survival associations across cancer types. High ANO8 expression shows unfavorable associations in KICH, KIRC and THCA, but favorable associations in HNSC, UVM and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ANO8 RNA expression.
This table summarizes ANO8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANO8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANO8 shows lower tumor expression in HNSC and higher tumor expression in COAD, BLCA, UCEC, STAD and LIHC. The COAD box plot shows higher ANO8 RNA expression in tumor versus normal tissue (log2 FC = +1.200, t-test p < 0.001).
This table shows molecular features associated with ANO8 in patient tissues and cancer cell lines. In patient samples, ANO8 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANO8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
